Search research articles
Contact Us
Filters
Showing results (11-20 of 50) with videos related to
Page
of 5
Sort By:
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
July 18, 2015
A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples
Yan Ren, Maria Wang, Suzana Couto, et al.
International Journal of Molecular Sciences
|
April 12, 2022
The Next Frontier: Translational Development of Ubiquitination, SUMOylation, and NEDDylation in Cancer
Nicole E Pellegrino, Arcan Guven, Kayleigh Gray, et al.
Blood
|
October 12, 2022
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma
Naser Ansari-Pour, Mehmet Samur, Erin Flynt, et al.
British Journal of Haematology
|
March 29, 2023
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial
Daniel L Menezes, Wendy L See, Alberto Risueño, et al.
British Journal of Haematology
|
August 4, 2017
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity
Patrick R Hagner, Hsiling Chiu, Maria Ortiz, et al.
JAMA Oncology
|
September 16, 2016
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis
Nikhil C Munshi, Herve Avet-Loiseau, Andy C Rawstron, et al.
Leukemia & Lymphoma
|
August 3, 2018
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS
Xiaozhong Qian, Meletios A Dimopoulos, Michael Amatangelo, et al.
Platelets
|
October 12, 2023
Multiple myeloma and its treatment contribute to increased platelet reactivity
Joanne L Mitchell, Dalia Khan, Rekha H Rana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 15, 2020
Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
William E Pierceall, Michael D Amatangelo, Nizar J Bahlis, et al.
British Journal of Haematology
|
June 16, 2026
Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial
Andrew Hall, James Croft, Katrina Walker, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 50) with videos related to
Sort By:
Page
of 5
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
July 18, 2015
A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples
Yan Ren, Maria Wang, Suzana Couto, et al.
International Journal of Molecular Sciences
|
April 12, 2022
The Next Frontier: Translational Development of Ubiquitination, SUMOylation, and NEDDylation in Cancer
Nicole E Pellegrino, Arcan Guven, Kayleigh Gray, et al.
Blood
|
October 12, 2022
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma
Naser Ansari-Pour, Mehmet Samur, Erin Flynt, et al.
British Journal of Haematology
|
March 29, 2023
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial
Daniel L Menezes, Wendy L See, Alberto Risueño, et al.
British Journal of Haematology
|
August 4, 2017
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity
Patrick R Hagner, Hsiling Chiu, Maria Ortiz, et al.
JAMA Oncology
|
September 16, 2016
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis
Nikhil C Munshi, Herve Avet-Loiseau, Andy C Rawstron, et al.
Leukemia & Lymphoma
|
August 3, 2018
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS
Xiaozhong Qian, Meletios A Dimopoulos, Michael Amatangelo, et al.
Platelets
|
October 12, 2023
Multiple myeloma and its treatment contribute to increased platelet reactivity
Joanne L Mitchell, Dalia Khan, Rekha H Rana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 15, 2020
Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
William E Pierceall, Michael D Amatangelo, Nizar J Bahlis, et al.
British Journal of Haematology
|
June 16, 2026
Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial
Andrew Hall, James Croft, Katrina Walker, et al.
Page
of 5